Changes in Hong Kong stocks | McPharmaceutical-B (02335) rose more than 5% and was recently included in the stock interconnection mechanism. Phase II clinical trial of MT200605 was completed

The Zhitong Finance App learned that McPharmaceutical-B (02335) rose more than 5% in the intraday period. As of press release, it had risen 5.67% to HK$21.98, with a turnover of HK$1.182 million.

According to the news, McPharmaceutical-B issued an announcement. According to the announcements issued by the Shanghai Stock Exchange and the Shenzhen Stock Exchange on September 4, 2026 and September 7, 2026, respectively, the company's H shares have been included in the list of eligible shares under the stock interconnection mechanism (Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect), which will take effect from September 7, 2026. After shares are included in the stock interconnection mechanism, eligible investors in mainland China can trade shares through the Shanghai Stock Exchange and Shenzhen Stock Exchange.

Earlier, Maike Pharmaceutical-B announced that the phase II clinical trial of MT200605, a candidate drug developed independently by the Group to treat acute ischemic stroke, has been completed. The clinical trial has proven to have significant and robust efficacy advantages and good safety.